IRCT20200105046010N100尚未招募未知
Bioequivalence study of Empagliflozin/ Linagliptin10/5 mg (JARLINO 10/5 mg) manufactured by Faran pharmed versus originate brand GLYXAMBI® Tab 10/5 mg. manufactured by ??Beohringer Ingelheim Germany in fasting condition in healthy volunteers
Faran Pharmed company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index 18-28
- •Informed consent
- •Age of 18-55 years old
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Empagliflozin/linagliptin
研究者
相似试验
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 10 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N69Cosar Pharmaceutical Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 25 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N59Darou darman Pars Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Empagliflozin 25 mg Combined Linagliptin 5 mg Tablet formulations.IRCT20180620040164N64Cosar Pharmaceutical Co.24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mgIRCT20200105046010N96???? ????? ?????24
招募中
Unknown
Bioequivalence study of Empagliflozin/Linagliptin 25/5 mg..IRCT20200105046010N99Kharazmi Company24